Literature DB >> 20447774

Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer.

Giorgio Arcangeli1, Jack Fowler, Sara Gomellini, Stefano Arcangeli, Biancamaria Saracino, Maria Grazia Petrongari, Marcello Benassi, Lidia Strigari.   

Abstract

PURPOSE: To compare the toxicity between hypofractionation vs. conventional fractionation schedules in patients with high-risk prostate cancer. METHODS AND MATERIALS: Between January 2003 and December 2007, 168 patients were randomized to receive either hypofractionated (62 Gy in 20 fractions within 5 weeks, 4 fractions/wk) or conventionally fractionated (80 Gy in 40 fractions within 8 weeks) three-dimensional conformal radiotherapy to the prostate and seminal vesicles. All patients had undergone a 9-month course of total androgen deprivation, with radiotherapy starting 2 months after initiation of the total androgen deprivation.
RESULTS: The median follow-up was 32 and 35 months in the hypofractionation and conventional fractionation arms, respectively. For the patients developing acute toxicity, no difference between the two fractionation groups was found in either severity or duration of gastrointestinal or genitourinary toxicity. Also, no difference was found in the incidence and severity of late gastrointestinal and genitourinary toxicity between the two treatment schedules, with a 3-year rate of Grade 2 or greater toxicity of 17% and 16% for the hypofractionation arm and 14% and 11% for the conventional fractionation arm, respectively. A statistically significant correlation between acute and late gastrointestinal toxicity was found only in the conventional fractionation group.
CONCLUSION: Our findings suggest that the hypofractionation regimen used in our study is safe, with only a slight, nonsignificant increase in tolerable and temporary acute toxicity compared with the conventional fractionation schedule. The severity and frequency of late complications was equivalent between the two treatment groups.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20447774     DOI: 10.1016/j.ijrobp.2009.12.045

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  54 in total

1.  Acute toxicity of hypofractionated intensity-modulated radiotherapy for prostate cancer.

Authors:  C S Drodge; O Boychak; S Patel; N Usmani; J Amanie; M B Parliament; A Murtha; C Field; S Ghosh; N Pervez
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

Authors:  Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler
Journal:  J Clin Oncol       Date:  2018-10-11       Impact factor: 44.544

3.  Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

Authors:  Jeffrey V Brower; Jeffrey D Forman; Patrick A Kupelian; Daniel G Petereit; Vinai Gondi; Colleen A Lawton; Nick Anger; Sandeep Saha; Rick Chappell; Mark A Ritter
Journal:  Radiother Oncol       Date:  2016-01-02       Impact factor: 6.280

4.  Single high-dose vs. fractionated radiotherapy: Effects on plant growth rates.

Authors:  Marc Guedea; Antoni Castel; Marc Arnalte; Alex Mollera; Victor Muñoz; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-24

5.  Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer.

Authors:  C Franzese; A Fogliata; G R D'Agostino; L Di Brina; T Comito; P Navarria; L Cozzi; M Scorsetti
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-08       Impact factor: 4.553

6.  Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients.

Authors:  Katarzyna Behrendt; Elżbieta Nowicka; Marzena Gawkowska-Suwińska; Grzegorz Plewicki; Beata Smolska-Ciszewska; Monika Giglok; Rafał Suwiński; Aleksander Zajusz
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

Review 7.  Systematic review of hypofractionated radiation therapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den
Journal:  Cancer Treat Rev       Date:  2013-03-01       Impact factor: 12.111

Review 8.  Hypofractionated radiotherapy for localized prostate cancer.

Authors:  Stefan Höcht; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Tobias Hölscher; Thomas Martin; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2016-09-14       Impact factor: 3.621

9.  Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis.

Authors:  Libin Sun; Linbin Sun; Shimiao Zhu; Yang Zhao; Hui Zhang; Zhiqun Shang; Ning Jiang; Gang Li; Yuanjie Niu
Journal:  Tumour Biol       Date:  2014-07-06

Review 10.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.